NCT04702698View on ClinicalTrials.gov

Effect of Food on Peposertib PK

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 14, 2021

Primary Completion Date

March 3, 2021

Study Completion Date

March 3, 2021

Conditions
Healthy
Interventions
DRUG

Peposertib

Participants will receive single oral dose of Peposertib tablet under fasting (Treatment A) or fed (Treatment B) conditions.

DRUG

Peposertib

Participants will receive oral suspension dose of peposertib tablets under fasted condition (Treatment C) in either period 1, 2 or 3 of part 1.

Trial Locations (2)

Unknown

Nuvisan GmbH, Gauting

Nuvisan GmbH, Neu-Ulm

All Listed Sponsors
lead

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT04702698 - Effect of Food on Peposertib PK | Biotech Hunter | Biotech Hunter